Orthofix Medical Inc

Orthofix Medical Inc(OFIX)の株式分析

$9.700

+0.071 (+0.73%)終値時点

Loading chart…
High
9.810
Open
9.640
VWAP
9.71
Vol
221.25K
Mkt Cap
505.89M
Low
9.610
Amount
2.15M
EV/EBITDA, TTM
5.09

Orthofix Medical Inc. is a global medical technology company. It offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System. Its Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. It provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. It offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation.

AI analysis of Orthofix Medical Inc (OFIX)

hold

Orthofix Medical Inc is currently trading at $9.70, which is significantly below the lowest analyst price target of $13, indicating potential upside. However, the stock has a low RSI of 34.59, suggesting it is oversold, but the recent 5-day change is down 3.10%, indicating continued weakness. The company has reduced its revenue guidance for 2026 to $845M-$855M, which is below the consensus of $843.31M, reflecting cautious market conditions. The main risk is the forward P/E ratio of 500, indicating potential overvaluation if earnings do not improve significantly in the near future.

Analyst Ratings (7)

+119.90% upside
Buy
6 Buy
1 Hold
0 Sell
Current: 9.70
安値
18.00
平均
21.33
高値
24.00

Canaccord

2026-08-10

目標株価

$13

Buy

Barrington

2026-08-06

目標株価

$14

Outperform

Stifel

2026-08-05

目標株価

$13

Buy

Stifel

2026-03-09

目標株価

$18

Buy

Canaccord

2026-02-26

目標株価

$20

Buy

バリュエーション指標

The current forward P/E ratio for Orthofix Medical Inc (OFIX) is 500.00, compared to its 5-year average forward P/E of 8.52.

Forward P/E

Strongly Overvalued
5Y Average P/E
8.52
Current P/E
500.00
割高
160.96
割安
-143.92

Forward EV/EBITDA

Undervalued
5Y Average EV/EBITDA
9.11
Current EV/EBITDA
5.09
割高
11.87
割安
6.36

Forward P/S

Undervalued
5Y Average P/S
0.81
Current P/S
0.45
割高
1.10
割安
0.52

Alphio AI Price Scenarios for OFIX

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%OFIX

$10.69

シナリオ価格

B

Base

Base · 50%OFIX

$10.56

シナリオ価格

B

Bear

Bear · 25%OFIX

$10.47

シナリオ価格

Whales holding OFIX

A

Armistice Capital LLC

+ HoldingOFIX

+13.92%

3M Return

P

Paradigm Capital Management, Inc.

+ HoldingOFIX

-14.65%

3M Return

イベントタイムライン

2026-08-05 (ET)

07:30:00

Orthofix Raises 2026 Net Sales Guidance to $845-$855 Million

07:30:00

Orthofix Reports Q2 Revenue of $210.9M, Beating Expectations

2026-07-06 (ET)

09:00:00

Nasdaq and S&P 500 Futures Rise as Chip Stocks Rebound

08:00:00

Orthofix Expects Medicare Reimbursement to Return to Pre-2026 Levels

2026-05-21 (ET)

10:00:00

Stock Down $2.38 to $9.77 in Morning Trading

ニュース

OFIX FAQ — answered by Alphio AI

Orthofix Medical Inc. is a global medical technology company. It offers a comprehensive portfolio of spinal hardware, bone growth therapies, limb reconstruction solutions, biologics and enabling technologies, including the 7D FLASH Navigation System. Its Global Spine segment offers two primary product categories: bone growth therapies and spinal implants, biologics, and enabling technologies. It provides implantable medical devices, biologics, enabling technologies, and other regenerative solutions which aim to restore the quality of life of patients suffering from diseases and traumas of the spine. It offers a variety of treatment solutions that incorporate multiple treatment modalities, such as mechanical, biological, and electromagnetic modes. Its Global Limb Reconstruction segment offers products and solutions for the underserved limb reconstruction market that encompasses four pillars: deformity correction, limb lengthening, complex fracture management, and limb preservation. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Orthofix Medical Inc is currently trading at $9.70, which is significantly below the lowest analyst price target of $13, indicating potential upside. However, the stock has a low RSI of 34.59, suggesting it is oversold, but the recent 5-day change is down 3.10%, indicating continued weakness. The company has reduced its revenue guidance for 2026 to $845M-$855M, which is below the consensus of $843.31M, reflecting cautious market conditions. The main risk is the forward P/E ratio of 500, indicating potential overvaluation if earnings do not improve significantly in the near future.

7 analysts cover OFIX: 6 rate it Buy, 1 Hold and 0 Sell. The average price target is 21.33.

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

無料で始める